<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01813929</url>
  </required_header>
  <id_info>
    <org_study_id>11-0693</org_study_id>
    <nct_id>NCT01813929</nct_id>
  </id_info>
  <brief_title>Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes</brief_title>
  <acronym>MeT1</acronym>
  <official_title>Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk&#xD;
      in type 1 diabetes (T1D). The purpose of this study is to measure the effect of metformin on&#xD;
      insulin sensitivity, vascular function and compliance, and mitochondrial function in T1D. The&#xD;
      long term goal is to identify novel non-glycemic approaches to managing cardiovascular&#xD;
      disease risk in T1D. The results of this study may validate a novel approach to T1D treatment&#xD;
      that could significantly improve current management of cardiovascular disease risk in this&#xD;
      high risk population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity by hyperinsulinemic euglycemic clamp</measure>
    <time_frame>End of each 6 week intervention period</time_frame>
    <description>Determine the effect of metformin on insulin sensitivity in T1D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow-mediated brachial artery dilation</measure>
    <time_frame>End of each 6 week intervention period</time_frame>
    <description>Measure of endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>End of each 6 week intervention period</time_frame>
    <description>PWV and AI by Sphygmacor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial measures</measure>
    <time_frame>End of each 6 week intervention period</time_frame>
    <description>Mito content and electron transport chain complexes, oxygen consumption with various substrates and max uncoupled O2 consumption. oxidant generation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic, inflammatory, vascular, and oxidative stress markers</measure>
    <time_frame>End of each 6 week intervention period</time_frame>
    <description>glucose, fatty acids, triglycerides, cholesterol, glycerol, insulin, lactate, counterregulatory hormones, IL6, TNF alpha, hsCRP, PAI-1, adiponection, TBARs, ICAM, endothelin-1, GSSG:GSH ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>End of each 6 week intervention period</time_frame>
    <description>measure of autonomic function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20-59 years of age,&#xD;
&#xD;
          -  Type 1 diabetes based on antibody-positivity, rapid persistent conversion to insulin&#xD;
             requirement after diagnosis, absent C-peptide, or DKA at diagnosis, or a clinical&#xD;
             course consistent with T1D,&#xD;
&#xD;
          -  HbA1c 6.0 - 9.5, and&#xD;
&#xD;
          -  Willing and able to commit to two 6 week-long periods of blinded medication followed&#xD;
             by hyperinsulinemic euglycemic clamp, vascular testing, and muscle biopsies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any comorbid condition associated with:&#xD;
&#xD;
               -  inflammation,&#xD;
&#xD;
               -  insulin Resistance, or&#xD;
&#xD;
               -  dyslipidemia including:&#xD;
&#xD;
                    1. cancer,&#xD;
&#xD;
                    2. heart failure,&#xD;
&#xD;
                    3. active or end stage liver disease,&#xD;
&#xD;
                    4. kidney disease, or&#xD;
&#xD;
                    5. rheumatological disease;&#xD;
&#xD;
          -  Tobacco use;&#xD;
&#xD;
          -  Pregnancy or women who are breastfeeding;&#xD;
&#xD;
          -  Steroid use;&#xD;
&#xD;
          -  Scheduled strenuous physical activity &gt;3 days a week;&#xD;
&#xD;
          -  Angina, known CAD, or any other cardiovascular or pulmonary disease;&#xD;
&#xD;
          -  A history of COPD or asthma;&#xD;
&#xD;
          -  Presence of systolic blood pressure &gt;190 at rest or &gt;250 with exercise, or diastolic&#xD;
             pressure &gt;95 at rest or &gt;105 with exercise;&#xD;
&#xD;
          -  Untreated thyroid disease;&#xD;
&#xD;
          -  Proteinuria (urine protein &gt;200 mg/dl) or a creatinine &gt; 1.5 mg/dl (males) or 1.4&#xD;
             mg/dL (females), suggestive of severe renal disease;&#xD;
&#xD;
          -  Severe Proliferative retinopathy;&#xD;
&#xD;
          -  Niacin treatment;&#xD;
&#xD;
          -  Administration of experimental agent for T1D within 30 days prior to screening;&#xD;
&#xD;
          -  Recent (prior 6 months) or current metformin or thiazolidenedione use;&#xD;
&#xD;
          -  Hypoglycemia unawareness or recurrent severe hypoglycemia (no symptoms of hypoglycemia&#xD;
             with FSBS&lt;40 and episodes of this severity &gt;1 per week);&#xD;
&#xD;
          -  Weight instability (weight change &gt;5% in last 6 months);&#xD;
&#xD;
          -  History of any organ transplant, including islet cell transplant;&#xD;
&#xD;
          -  Current or prior infection with HIV, hepatitis B or hepatitis C or hepatic&#xD;
             -insufficiency (AST or ALT &gt; 2x the upper limits of normal);&#xD;
&#xD;
          -  Any condition, medical or otherwise that would, in the opinion of the investigator,&#xD;
             prevent complete participation in the study, or that would pose a significant hazard&#xD;
             to the subject;&#xD;
&#xD;
          -  History of substance abuse within the 12 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Schauer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2013</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin</keyword>
  <keyword>Metformin</keyword>
  <keyword>Vascular</keyword>
  <keyword>Vessels</keyword>
  <keyword>Type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 7, 2021</submitted>
    <returned>November 5, 2021</returned>
    <submitted>November 5, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

